UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals as Gattex and Natpara Could Provide Meaningful Annuities
October 03, 2013 at 10:17 AM EDT
In a report published Thursday, Bank of America analyst Tazeen Ahmad initiated coverage on NPS Pharmaceuticals (NASDAQ: NPSP ) with a Buy rating and $46.00 price target. In the report, Bank of America noted, “We are initiating coverage of NPS Pharmaceuticals (NPSP) with a Buy rating and PO of $46.
